{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:21Z","timestamp":1791478221205,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.vaccine.2013.01.021","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T12:02:17Z","timestamp":1359028937000},"page":"1569-1575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults"],"prefix":"10.1016","volume":"31","author":[{"given":"Helen S.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Baber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.01.021_bib0005","doi-asserted-by":"crossref","unstructured":"AUMSP. The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2010. Commun Dis Intell 2011; 35(3):217\u201328.","DOI":"10.33321\/cdi.2011.35.20"},{"key":"10.1016\/j.vaccine.2013.01.021_bib0010","unstructured":"UK Health Protection Agency. Meningococcal Reference Unit: All laboratory confirmed cases of invasive meningococcal disease by serogroup, age and calendar year: England and Wales, 2000\u20132010. Available at: http:\/\/www.hpa.org.uk\/web\/HPAweb&HPAwebStandard\/HPAweb_C\/1272032921946 [accessed 19.07.12]"},{"issue":"12","key":"10.1016\/j.vaccine.2013.01.021_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. (2)","key":"10.1016\/j.vaccine.2013.01.021_bib0020","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"9\/10","key":"10.1016\/j.vaccine.2013.01.021_bib0025","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2013.01.021_bib0030","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/CVI.05655-11","article-title":"Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction","volume":"19","author":"Ishola","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"7659","key":"10.1016\/j.vaccine.2013.01.021_bib0035","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.vaccine.2013.01.021_bib0040","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2013.01.021_bib0045","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1. 7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.01.021_bib0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/CDLI.7.3.390-395.2000","article-title":"Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread","volume":"7","author":"Jelfs","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2013.01.021_bib0055","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","article-title":"Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. the active bacterial core surveillance team","volume":"38","author":"Tondella","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2013.01.021_bib0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.01.021_bib0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2013.01.021_bib0070","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2013.01.021_bib0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2013.01.021_bib0080","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2013.01.021_bib0085","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.01.021_bib0090","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"37","key":"10.1016\/j.vaccine.2013.01.021_bib0095","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"issue":"25-26","key":"10.1016\/j.vaccine.2013.01.021_bib0100","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2013.01.021_bib0105","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","article-title":"Perez JL. A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults","volume":"8","author":"Sheldon","year":"2012","journal-title":"Hum Vaccine Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2013.01.021_bib0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2013.01.021_bib0115","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2013international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.01.021_bib0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4161\/hv.18500","article-title":"Bexsero: a multicomponent vaccine for prevention of meningococcal disease","volume":"8","author":"Gorringe","year":"2012","journal-title":"Hum Vaccine Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2013.01.021_bib0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erv.11.50","article-title":"New frontiers in meningococcal vaccines","volume":"10","author":"Anderson","year":"2011","journal-title":"Expert Rev Vaccine"},{"issue":"9816","key":"10.1016\/j.vaccine.2013.01.021_bib0130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:19:21Z","timestamp":1759400361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0264410X13000789"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.01.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}